Skip to main content
Pain crises in sickle cell patients diminished with crizanlizumab
10/19/2018

Based on post hoc analysis from its midstage SUSTAIN study, Novartis reported that nearly 36% of sickle cell patients treated with crizanlizumab, or SEG101, did not experience post-treatment pain crises, compared with 16.9% of patients given a placebo. Findings were published in the American Journal of Hematology.

Full Story: